Medivation (NASDAQ:MDVN)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a report released on Monday, AmericanBankingNews.com reports. They currently have a $72.00 price objective on the stock. Chardan Capital’s price target indicates a potential upside of 19.52% from the company’s current price.
Shares of Medivation (NASDAQ:MDVN) opened at 60.24 on Monday. Medivation has a 52-week low of $41.89 and a 52-week high of $59.86. The stock has a 50-day moving average of $57.49 and a 200-day moving average of $52.09. The company’s market cap is $4.531 billion.
Medivation (NASDAQ:MDVN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.14. The company had revenue of $70.15 million for the quarter, compared to the consensus estimate of $59.35 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The company’s quarterly revenue was up 63.5% on a year-over-year basis. On average, analysts predict that Medivation will post $-0.90 earnings per share for the current fiscal year.
MDVN has been the subject of a number of other recent research reports. Analysts at Maxim Group raised their price target on shares of Medivation from $66.00 to $71.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Aegis reiterated a “buy” rating on shares of Medivation in a research note to investors on Tuesday, October 22nd. Finally, analysts at Zacks downgraded shares of Medivation from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, August 28th. They now have a $59.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $66.17.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.